Pdt Partners, LLC Xencor Inc Transaction History

Pdt Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$18.21 - $24.5 $418,192 - $562,642	22,965 New	22,965 $434,000
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $212,790 - $280,378	8,643 New	8,643 $225,000
Q1 2022 May 16, 2022	SELL	$26.68 - $41.63 $1.1 Million - $1.72 Million	-41,399 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$33.67 - $43.44 $148,114 - $191,092	4,399 Added 11.89%	41,399 $1.66 Million
Q2 2021 Aug 16, 2021	SELL	$34.33 - $44.68 $137 - $178	-4 Reduced 0.01%	37,000 $1.28 Million
Q1 2021 May 17, 2021	SELL	$40.81 - $53.88 $257,062 - $339,390	-6,299 Reduced 14.55%	37,004 $1.59 Million
Q4 2020 Feb 16, 2021	BUY	$36.63 - $47.63 $149,816 - $194,806	4,090 Added 10.43%	43,303 $1.89 Million
Q3 2020 Nov 16, 2020	SELL	$30.09 - $43.02 $144,853 - $207,098	-4,814 Reduced 10.93%	39,213 $1.52 Million
Q2 2020 Aug 14, 2020	BUY	$27.76 - $33.42 $1.22 Million - $1.47 Million	44,027 New	44,027 $1.43 Million

216

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.